Free Trial

Invesco Ltd. Buys 11,662 Shares of CG Oncology, Inc. (NASDAQ:CGON)

CG Oncology logo with Medical background

Invesco Ltd. boosted its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 75.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,069 shares of the company's stock after purchasing an additional 11,662 shares during the period. Invesco Ltd.'s holdings in CG Oncology were worth $776,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. NEOS Investment Management LLC increased its position in shares of CG Oncology by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock valued at $239,000 after acquiring an additional 817 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of CG Oncology by 2.2% in the 4th quarter. Rhumbline Advisers now owns 69,016 shares of the company's stock valued at $1,979,000 after buying an additional 1,458 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of CG Oncology by 16.7% in the 4th quarter. New York State Common Retirement Fund now owns 13,996 shares of the company's stock valued at $401,000 after buying an additional 2,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in CG Oncology during the fourth quarter worth $68,000. Finally, KLP Kapitalforvaltning AS bought a new stake in CG Oncology during the fourth quarter worth $100,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CGON shares. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research note on Monday, April 28th. Scotiabank began coverage on CG Oncology in a research note on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 price target for the company. Royal Bank of Canada lifted their price target on shares of CG Oncology from $66.00 to $68.00 and gave the company an "outperform" rating in a research report on Tuesday, April 29th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, April 28th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $55.00 price target on shares of CG Oncology in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $57.70.

View Our Latest Stock Analysis on CG Oncology

CG Oncology Trading Up 1.7 %

NASDAQ:CGON traded up $0.37 during mid-day trading on Thursday, hitting $22.71. 378,000 shares of the company's stock were exchanged, compared to its average volume of 802,432. CG Oncology, Inc. has a fifty-two week low of $14.80 and a fifty-two week high of $40.47. The firm has a market capitalization of $1.73 billion, a P/E ratio of -15.99 and a beta of 1.08. The company has a 50 day simple moving average of $23.61 and a 200-day simple moving average of $28.75.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.11 million. As a group, analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $30.76, for a total value of $30,760.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

About CG Oncology

(Free Report)

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

See Also

Institutional Ownership by Quarter for CG Oncology (NASDAQ:CGON)

Should You Invest $1,000 in CG Oncology Right Now?

Before you consider CG Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.

While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines